Table 1.
Characteristics of the Study Population
| n = 276 | ||
|---|---|---|
| Demographics | Age, mean (SD) | 13.2 (2.4) |
| Sex, % female | 43.8 | |
| Race White African-American Hispanic Asian Multiracials |
90.6 4.1 6.9 0.3 5.0 |
|
| Highest parental education 12th grade Some college College Graduate school |
2.8 13.2 37.6 46.4 |
|
| Disease Characteristics | % In remission | 82.9 |
| Age at diagnosis, mean (SD) | 9.8 (3.0) | |
| Therapy | Historical therapy, % 5-Aminosalicylates Immunomodulators Biologics Corticosteroids Surgery |
63.4 74.6 61.2 86.6 16.7 |
| Current therapy, % 5-Aminosalicylates Immunomodulators Biologics Corticosteroids |
27.9 47.1 54.0 9.8 |
|
| Disease-Specific Measures | Disease-Specific Activity Scores, mean (SD)SCDAIa | 102 (71) |
| Health Related Quality of Live Scores, mean (SD) IMPACT-35b | 131 (22) | |
| Disease Activity within the last 6 months, mean (SD) Manitobac | 4 (2) | |
| PROMIS measures | PROMIS T-scores, mean (SD) Anxiety Depression Fatigue Pain interference Peer relationships |
47 (11) 43 (8) 48 (12) 48 (11) 49 (9) |
a
3-item questionnaire of Crohn’s disease activity, score < 150 indicates remission
b
35-item, self-administered questionnaire of health-related QoL in children with IBD, scores range 35 (poor) to 175 (best)
c
1-item questionnaire of IBD activity within the prior 6 months. A score of 4 indicates “occasional” activity